Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical
implications for patients and significant economic consequences for society. The prevalence …

This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …

Background Patients with chronic obstructive pulmonary disease (COPD) with an
eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal …

Background The short-term benefits of inhaled corticosteroids for patients with chronic
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …

Background Blood eosinophil counts might predict response to inhaled corticosteroids (ICS)
in patients with chronic obstructive pulmonary disease (COPD) and a history of …

Background Treatment with inhaled glucocorticoids in combination with long-acting
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …

Background Previous studies have highlighted a relationship between reduction in rate of
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …

Objective We performed a review of studies of fluticasone propionate (FP)/salmeterol
(SAL)(combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients …

Background Roflumilast reduces exacerbations in patients with severe chronic obstructive
pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids …